Table 1.
Overview of the functional and anatomic results of bevacizumab.
| Study | Ref. | Duration (w) | Regimen | N (eyes) | BCVA (ETDRS letters) | CRT (µm) | ||
|---|---|---|---|---|---|---|---|---|
| Baseline | Changea | Baseline | Change | |||||
| DRCR.neta | [29] | 12 | Laser | 19 | 64 (50 to 70) | −1 (−6 to 5) | 441 (354 to 512) | −40 (−146 to 85) |
| Beva I | 22 | 65 (60 to 70) | 5 (1 to 12)∗ | 397 (320 to 358) | −56 (−120 to −6) | |||
| Beva II | 24 | 63 (57 to 71) | 7 (4 to 11)∗ | 446 (342 to 543) | −47 (−125 to −16) | |||
| Beva III | 22 | 64 (52 to 68) | 4 (−3 to 7) | 406 (353 to 520) | −5 (−41 to 53) | |||
| Beva IV | 22 | 66 (57 to 72) | 0 (−5 to 8) | 389 (308 to 452) | −40 (−103 to 33) | |||
|
| ||||||||
| BOLTb | [30] | 52 | Beva 1.25 mg | 42 | 55.7 (9.7) | 8 (1 to 10)∗∗ | 507 (145) | −130 (122) |
| Laser | 38 | 54.6 (8.6) | −0.5 (−15 to 5) | 481 (121) | −68 (171) | |||
| [31] | 104 | Beva 1.25 mg | 42 | 55.7 (9.7) | 8.6∗∗ | 507 (145) | −146 | |
| Laser | 38 | 54.6 (8.6) | 0.5 | 481 (121) | −118 | |||
|
| ||||||||
| Nepomuceno et al.c | [32] | 48 | Beva 1.5 mg | 32 | 0.60 (0.05) | 0.36 (0.05) | 451.7 (22.3) | −122.0 (20.9) |
| Rani 0.5 mg | 28 | 0.63 (0.06) | 0.34 (0.04) | 421.9 (23.1) | −141.0 (18.6) | |||
|
| ||||||||
| Kriechbaum et al.c | [33] | 52 | Beva 2.5 mg | 15 | 0.30 (0.19 to 0.42) | 0.18 (0.06 to 0.3) | 505 (438 to 572) | 351 (258 to 445) |
| Triam 8 mg | 15 | 0.32 (0.2 to 0.43) | 0.36 (0.19 to 0.52) | 490 (433 to 547) | 296 (224 to 368) | |||
|
| ||||||||
| Sonoda et al.c | [34] | 12 | Beva 1.25 mg | 26 | 0.48 (0.32) | 0.40 (0.25) | 495.7 (195.3) | 449.7 (212.2) |
| Triam 4 mg | 25 | 0.40 (0.25) | 0.31 (0.23) | 503.9 (171.4) | 389.4 (209.4) | |||
Note. aData are expressed in median (interquartile range). bData are expressed in mean (standard deviation). cMean (standard deviation) best-corrected visual acuity (logMAR) at baseline and at the last follow-up visit. ∗p < 0.01 vs. laser. ∗∗p < 0.001 vs. laser. w: weeks; BCVA: best-corrected visual acuity; EDTRS: Early Treatment of Diabetic Retinopathy Study; CRT: central retina thickness; DRCR.net: Diabetic Retinopathy Clinical Research Network; Beva I: intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks; Beva II: intravitreal injection of 2.5 mg of bevacizumab at baseline and 6 weeks; Beva III: intravitreal injection of 1.25 mg of bevacizumab at baseline and sham injection at 6 weeks; Beva IV: intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks with photocoagulation at 3 weeks; Beva: bevacizumab; Rani: ranibizumab; Triam: triamcinolone acetonide.